Fountzilas, George <br/><br/>
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.  [electronic resource] 

 -  Oncotarget  May 2016 
 - 32731-53 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.9022  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>Biomarkers, Tumor--analysis<br/>Chemotherapy, Adjuvant<br/>Chi-Square Distribution<br/>Class I Phosphatidylinositol 3-Kinases--analysis<br/>Clinical Trials as Topic<br/>DNA Mutational Analysis<br/>Disease Progression<br/>Disease-Free Survival<br/>Female<br/>Genetic Predisposition to Disease<br/>Greece<br/>Humans<br/>Immunohistochemistry<br/>Kaplan-Meier Estimate<br/>Middle Aged<br/>Multivariate Analysis<br/>Mutation<br/>Patient Selection<br/>Phenotype<br/>Predictive Value of Tests<br/>Proportional Hazards Models<br/>Prospective Studies<br/>Retrospective Studies<br/>Risk Factors<br/>Time Factors<br/>Trastuzumab--therapeutic use<br/>Treatment Outcome<br/>Triple Negative Breast Neoplasms--chemistry<br/>Tumor Suppressor Protein p53--analysis<br/>Young Adult